BTIG Research reissued their neutral rating on shares of Poseida Therapeutics (NASDAQ:PSTX – Free Report) in a report issued on Tuesday, Marketbeat reports.
Several other analysts have also commented on the stock. HC Wainwright restated a “neutral” rating and issued a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a report on Tuesday. William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.50.
Get Our Latest Stock Report on PSTX
Poseida Therapeutics Trading Down 0.2 %
Insiders Place Their Bets
In other news, Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the transaction, the chairman now directly owns 651,291 shares of the company’s stock, valued at $6,037,467.57. This represents a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 2.90% of the company’s stock.
Hedge Funds Weigh In On Poseida Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Bayesian Capital Management LP bought a new position in shares of Poseida Therapeutics in the first quarter worth approximately $33,000. Marshall Wace LLP bought a new stake in Poseida Therapeutics during the second quarter valued at about $31,000. Rothschild Investment LLC purchased a new position in shares of Poseida Therapeutics in the second quarter valued at about $35,000. Principal Financial Group Inc. bought a new position in shares of Poseida Therapeutics in the second quarter worth about $35,000. Finally, Virtu Financial LLC purchased a new stake in shares of Poseida Therapeutics during the third quarter worth about $37,000. 46.87% of the stock is currently owned by hedge funds and other institutional investors.
Poseida Therapeutics Company Profile
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Further Reading
- Five stocks we like better than Poseida Therapeutics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- What is Forex and How Does it Work?
- 3 Penny Stocks Ready to Break Out in 2025
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.